HR c.1150_1152delinsATG ;(p.L384M)

Variant ID: 8-21984803-GAG-CAT

NM_005144.4(HR):c.1150_1152delinsATG;(p.L384M)

This variant was identified in 8 publications

View GRCh38 version.




Publications:


Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.

Targeted Oncology
Castagnetti, Fausto F; Binotto, Gianni G; Capodanno, Isabella I; Billio, Atto A; Calistri, Elisabetta E; Cavazzini, Francesco F; Crugnola, Monica M; Gozzini, Antonella A; Gugliotta, Gabriele G; Krampera, Mauro M; Lucchesi, Alessandro A; Merli, Anna A; Miggiano, Maria Cristina MC; Minotto, Claudia C; Poggiaspalla, Monica M; Salvucci, Marzia M; Scappini, Barbara B; Tiribelli, Mario M; Trabacchi, Elena E; Rosti, Gianantonio G; Galimberti, Sara S; Bonifacio, Massimiliano M
Publication Date: 2021-11

Variant appearance in text: HR: L384M
PubMed Link: 34661826
Variant Present in the following documents:
  • Main text
View BVdb publication page



Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature.

International Journal Of Hematology-Oncology And Stem Cell Research
Amouei, Asiyeh A; Daeian, Nesa N; Khezrnia, Seyedeh Sana SS; Mansouri, Ava A; Hadjibabaie, Molouk M
Publication Date: 2021-04-01

Variant appearance in text: HR: L384M
PubMed Link: 34466210
Variant Present in the following documents:
  • Main text
  • IJHOSCR-15-114.pdf
View BVdb publication page



Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Asian Pacific Journal Of Cancer Prevention : Apjcp
Iqbal, Zafar Z; Absar, Muhammad M; Mahmood, Amer A; Aleem, Aamer A; Iqbal, Mudassar M; Jameel, Abid A; Akhtar, Tanveer T; Karim, Sajjad S; Rasool, Mahmood M; Mirza, Zeenat Z; Khalid, Muhammad M; Akram, Afia Muhammad AM; Sabar, Muhammad Farooq MF; Khalid, Ahmad M AM; Aljarrah, Khalid K; Iqbal, Janhangir J; Khalid, Muhammad M; Shah, Ijaz H IH; Alanazi, Nawaf N
Publication Date: 2020-12-01

Variant appearance in text: HR: L384M
PubMed Link: 33369447
Variant Present in the following documents:
  • Main text
  • APJCP-21-3517.pdf
View BVdb publication page



Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.

American Journal Of Hematology
Cortes, Jorge E JE; Khoury, Hanna J HJ; Kantarjian, Hagop M HM; Lipton, Jeff H JH; Kim, Dong-Wook DW; Schafhausen, Philippe P; Matczak, Ewa E; Leip, Eric E; Noonan, Kay K; Brümmendorf, Tim H TH; Gambacorti-Passerini, Carlo C
Publication Date: 2016-12

Variant appearance in text: HR: L384M
PubMed Link: 27531525
Variant Present in the following documents:
  • Main text
  • AJH-91-1206.pdf
View BVdb publication page



[Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
Jiang, Qian Q; Qin, Yazhen Y; Lai, Yueyun Y; Jiang, Hao H; Shi, Hongxia H
Publication Date: 2016-01

Variant appearance in text: HR: L384M
PubMed Link: 26876246
Variant Present in the following documents:
  • Main text
  • cjh-37-01-007.pdf
View BVdb publication page



Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance.

Iranian Journal Of Cancer Prevention
Rejali, Leili L; Poopak, Behzad B; Hasanzad, Mandana M; Sheikhsofla, Fatemeh F; Varnoosfaderani, Ameneh Saadat AS; Safari, Nazila N; Rabieipoor, Saghar S
Publication Date: 2015-05

Variant appearance in text: HR: L384M
PubMed Link: 26413254
Variant Present in the following documents:
  • Main text
  • ijcp-08-2334.pdf
View BVdb publication page



Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.

Clinical Lymphoma, Myeloma & Leukemia
Cornelison, A Megan AM; Kantarjian, Hagop H; Cortes, Jorge J; Jabbour, Elias E
Publication Date: 2011-06

Variant appearance in text: HR: L384M
PubMed Link: 22035738
Variant Present in the following documents:
  • Main text
View BVdb publication page



Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review.

Core Evidence
Jabbour, Elias E; Cortes, Jorge J; Kantarjian, Hagop H
Publication Date: 2010-06-15

Variant appearance in text: HR: L384M
PubMed Link: 20694077
Variant Present in the following documents:
  • Main text
  • ce-4-207.pdf
View BVdb publication page